Exiqon Completes Assays for Tacere, Pfizer RNAi Drug Alliance
September 17, 2009
Exiqon Completes Assays for Tacere, Pfizer RNAi Drug Alliance
Exiqon said that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tacere Takes Back Asian Rights to HCV Program as It Waits on Pfizer
February 10, 2011 / Gene Silencing News - Tacere Considers Sale of Company as Pfizer Exercises Option to HCV Program
February 11, 2010 / Gene Silencing News - Benitec Looks to Outlicense IP While Avoiding Litigation Mistakes of Its Past
November 8, 2012 / Gene Silencing News - Tacere Said to be Looking for New Partner for HCV Drug Candidate
June 21, 2012 / Gene Silencing News - Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
December 9, 2010 / Gene Silencing News